KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Gross Margin (2016 - 2025)

Historic Gross Margin for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to 62.83%.

  • Emergent BioSolutions' Gross Margin rose 45600.0% to 62.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 105.83%, marking a year-over-year increase of 169600.0%. This contributed to the annual value of 73.55% for FY2024, which is 26800.0% up from last year.
  • Emergent BioSolutions' Gross Margin amounted to 62.83% in Q3 2025, which was up 45600.0% from 52.52% recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Gross Margin ranged from a high of 247.56% in Q4 2024 and a low of 6.94% during Q1 2023
  • In the last 5 years, Emergent BioSolutions' Gross Margin had a median value of 60.12% in 2025 and averaged 76.16%.
  • In the last 5 years, Emergent BioSolutions' Gross Margin soared by 1219100bps in 2022 and then plummeted by -667200bps in 2023.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Gross Margin stood at 39.9% in 2021, then surged by 306bps to 161.81% in 2022, then increased by 10bps to 177.62% in 2023, then surged by 39bps to 247.56% in 2024, then crashed by -75bps to 62.83% in 2025.
  • Its Gross Margin stands at 62.83% for Q3 2025, versus 52.52% for Q2 2025 and 60.17% for Q1 2025.